Dabl / Tripl test
DABL TEST in pregnant women determines an increased risk of homozyme anomalies.
This screening is important between 11 and 14 weeks of pregnancy. It includes an ultrasound examination to determine the exact week of pregnancy, measure the size of the fetus, the thickness of the fold on the neck and nasal bone, indicating the existence of Daun’s syndrome. Then the mother’s blood is removed and a special program calculates the risk of the mother carrying an anomaly child. The blood test measures the level of the presence of three hormones in the mother’s blood, alpha-fetoproteins and hormones, and human coronary gonadotropin, which indicate the possible risk of chromosomal anomalies. Border risk is one versus 250. In cases where the risk of access to invasive diagnostics is determined. If the doctor estimates that the Tripl test is also required.
TRIPL TESTIt is important to do between 15 and 18 weeks of pregnancy, and the optimal time is 16 weeks of pregnancy. The triple test should primarily be done for pregnant women who are more likely to have a child with chromosomal anomaly, primarily with trisomy 21 (sy Down) and trisomy 18 (ie, sy Edvards). The name of the triple test, that is, the triple test, tells of the values of 33 hormones from the blood of the pregnant woman (AFP, Hcg, uE3). The values of the hormone are correlated with the age of the pregnant woman, determined by ultrasound measurement of the fetus and several other parameters, and the result is a certain probability of chromosomalopathy. Based on the results, an accurate diagnosis can not be made. It only serves as a method of selecting those who need to make a definitive, or accurate diagnosis (early amniocentesis) later on. Only the amniocentesis result is definitive, ie. finite.
The reliability of the tests is 80%.
The only way to do diagnosis with a degree of confidence of 99% is amniocentesis, or taking water for analysis. However, this is an invasive method, and therefore screening tests have been introduced, which reveal anomalies in the fetus.